MA47608A - Anticorps humanisé pour le traitement ou la prévention de troubles cognitifs, son procédé de production et agent pour le traitement ou la prévention de troubles cognitifs l'utilisant - Google Patents

Anticorps humanisé pour le traitement ou la prévention de troubles cognitifs, son procédé de production et agent pour le traitement ou la prévention de troubles cognitifs l'utilisant

Info

Publication number: MA47608A
Authority: MA; Morocco
Prior art keywords: prevention; treatment; cognitive disorders; agent; production process
Prior art date: 2017-02-27

Application number

MA047608A

Other languages

English (en)

Inventor

Jeanne E Baker

Hiroshi Eguchi

Angela Marie Jablonski

Daniel Stephen Malashock

Carl Mieczkowski

Takashi Murakami

Naoko Namiki

Batteur Sophie Parmentier

Gopalan Raghunathan (Raghu)

Akira Tanokura

Original Assignee

Merck Sharp & Dohme

Teijin Pharma Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-02-27

Filing date

2018-02-27

Publication date

2020-01-01

2018-02-27 Application filed by Merck Sharp & Dohme, Teijin Pharma Ltd filed Critical Merck Sharp & Dohme

2020-01-01 Publication of MA47608A publication Critical patent/MA47608A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

MA047608A 2017-02-27 2018-02-27 Anticorps humanisé pour le traitement ou la prévention de troubles cognitifs, son procédé de production et agent pour le traitement ou la prévention de troubles cognitifs l'utilisant MA47608A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2017035594A JP2018139530A (ja)	2017-02-27	2017-02-27	認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤

Publications (1)

Publication Number	Publication Date
MA47608A true MA47608A (fr)	2020-01-01

Family

ID=62025891

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA047608A MA47608A (fr)	2017-02-27	2018-02-27	Anticorps humanisé pour le traitement ou la prévention de troubles cognitifs, son procédé de production et agent pour le traitement ou la prévention de troubles cognitifs l'utilisant

Country Status (26)

Country	Link
US (3)	US10556950B2 (fr)
EP (1)	EP3585810B1 (fr)
JP (4)	JP2018139530A (fr)
KR (1)	KR102701634B1 (fr)
CN (2)	CN110382528A (fr)
AR (2)	AR110875A1 (fr)
AU (1)	AU2018224390C1 (fr)
BR (1)	BR112019016490A2 (fr)
CA (1)	CA3052538A1 (fr)
CL (3)	CL2019002296A1 (fr)
CO (1)	CO2019008786A2 (fr)
CR (1)	CR20190363A (fr)
DO (1)	DOP2019000215A (fr)
EA (1)	EA201991726A1 (fr)
GE (2)	GEAP202215170A (fr)
IL (1)	IL267945B2 (fr)
JO (1)	JOP20180014A1 (fr)
MA (1)	MA47608A (fr)
MX (2)	MX2019009945A (fr)
MY (1)	MY193821A (fr)
NI (1)	NI201900086A (fr)
PE (2)	PE20191614A1 (fr)
PH (1)	PH12019501929A1 (fr)
SG (2)	SG11201907548PA (fr)
TW (2)	TW202506718A (fr)
WO (2)	WO2018154392A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI777183B (zh) *	2012-05-31	2022-09-11	公立大學法人大阪市立大學	失智症治療劑或預防劑
JP2020508054A (ja)	2017-02-17	2020-03-19	デナリセラピューティクスインコーポレイテッドＤｅｎａｌｉＴｈｅｒａｐｅｕｔｉｃｓＩｎｃ．	抗タウ抗体及びその使用方法
JP2018139530A (ja) *	2017-02-27	2018-09-13	帝人ファーマ株式会社	認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
UA129617C2 (uk)	2017-10-16	2025-06-18	Еісаі Р Енд Д Менеджмент Ко., Лтд.	Антитіло до тау та його застосування
US20210355199A1 (en)	2018-06-28	2021-11-18	University Of Virginia Patent Foundation	Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling
US12365724B2 (en) *	2018-12-10	2025-07-22	New York University	Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof
US20220381790A1 (en)	2019-02-11	2022-12-01	University Of Virginia Patent Foundation	Selection and blockade of fertilization competent male and female gametes
WO2020186247A1 (fr)	2019-03-13	2020-09-17	University Of Virginia Patent Foundation	Compositions et méthodes pour favoriser la viabilité des îlots et améliorer la sécrétion d'insuline
JP7181438B2 (ja) *	2019-08-06	2022-11-30	アプリノイアセラピューティクスリミテッド	病理学的タウ種に結合する抗体及びその使用
IL296519A (en) *	2020-06-02	2022-11-01	Teijin Pharma Ltd	Anti-igf-1 receptor humanized antibody
US20230265175A1 (en) *	2020-06-25	2023-08-24	Merck Sharp & Dohme Llc	High affinity antibodies targeting tau phosphorylated at serine 413
US20250034559A1 (en)	2021-11-17	2025-01-30	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
CN115322255B (zh) *	2022-04-25	2025-03-07	上海药明生物医药有限公司	一种优化的Fc变体及其应用
KR20250069606A (ko)	2022-09-15	2025-05-19	보이저 테라퓨틱스, 인크.	타우 결합 화합물
WO2025122634A1 (fr)	2023-12-05	2025-06-12	Voyager Therapeutics, Inc.	Compositions et méthodes pour le traitement de troubles liés à la protéine tau
WO2025207501A1 (fr) *	2024-03-26	2025-10-02	Merck Sharp & Dohme Llc	Cristaux d'anticorps monoclonal anti-tau humain
CN119080924B (zh) *	2024-07-04	2025-02-25	上海交通大学医学院附属第九人民医院	一种单克隆免疫球蛋白及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS587390B2 (ja)	1975-03-11	1983-02-09	ツキシマキカイカブシキガイシヤ	ア−クヨウセツホウホウ
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
EP0940468A1 (fr)	1991-06-14	1999-09-08	Genentech, Inc.	Domaine variable d'un anticorps humanisé
WO1994004679A1 (fr)	1991-06-14	1994-03-03	Genentech, Inc.	Procede pour fabriquer des anticorps humanises
JP3587390B2 (ja)	1994-03-17	2004-11-10	タカラバイオ株式会社	リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法
JP4754352B2 (ja)	2003-08-29	2011-08-24	株式会社リバース・プロテオミクス研究所	タンパク質の固定化方法
JP2007512846A (ja)	2003-12-04	2007-05-24	ゼンコー・インコーポレイテッド	増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
UA107571C2 (xx)	2009-04-03	2015-01-26		Фармацевтична композиція
US8609097B2 (en)	2009-06-10	2013-12-17	Hoffmann-La Roche Inc.	Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP2625198B1 (fr)	2010-10-07	2015-07-22	AC Immune S.A.	Anticorps dirigés contre tau phosphorylée
US8940272B2 (en) *	2010-10-11	2015-01-27	University Of Zurich	Human anti-tau antibodies
DK2794654T3 (da)	2011-12-20	2019-08-05	Janssen Biotech Inc	Anti-phf-tau-antistoffer og deres anvendelser
TWI777183B (zh) *	2012-05-31	2022-09-11	公立大學法人大阪市立大學	失智症治療劑或預防劑
SI2885010T1 (sl) *	2012-08-16	2020-07-31	Ipierian, Inc.	Metode zdravljenja tauopatije
BR112015014751A8 (pt)	2012-12-21	2018-01-16	Biogen Int Neuroscience Gmbh	anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
EA039554B1 (ru)	2013-06-10	2022-02-09	АйПИЕРИАН, ИНК.	Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости
AU2014368696A1 (en)	2013-12-20	2016-06-02	F. Hoffmann-La Roche Ag	Humanized anti-Tau(pS422) antibodies and methods of use
AR100978A1 (es) *	2014-06-26	2016-11-16	Hoffmann La Roche	LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI664190B (zh) *	2014-06-27	2019-07-01	美商Ｃ２Ｎ醫療診斷有限責任公司	人類化抗－ｔａｕ抗體
RU2017119185A (ru)	2014-11-05	2018-12-05	Дженентек, Инк.	Антитела против fgfr2/3 и способы их применения
WO2016112078A2 (fr)	2015-01-08	2016-07-14	Janssen Biotech, Inc.	Anticorps tau/anti-phf et leurs utilisations
TN2017000543A1 (en)	2015-07-06	2019-04-12	Ucb Biopharma Sprl	Tau-binding antibodies
MA41670A1 (fr)	2015-07-06	2018-05-31	Ucb Biopharma Sprl	Anticorps se liant a tau
JO3711B1 (ar)	2015-07-13	2021-01-31	H Lundbeck As	أجسام مضادة محددة لبروتين تاو وطرق استعمالها
JP2018139530A (ja)	2017-02-27	2018-09-13	帝人ファーマ株式会社	認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤

2017
- 2017-02-27 JP JP2017035594A patent/JP2018139530A/ja active Pending
- 2017-02-27 JO JOP/2018/0014A patent/JOP20180014A1/ar unknown
2018
- 2018-02-25 WO PCT/IB2018/000267 patent/WO2018154392A1/fr not_active Ceased
- 2018-02-26 TW TW113125487A patent/TW202506718A/zh unknown
- 2018-02-26 TW TW107106444A patent/TWI848904B/zh active
- 2018-02-27 PE PE2019001541A patent/PE20191614A1/es unknown
- 2018-02-27 SG SG11201907548PA patent/SG11201907548PA/en unknown
- 2018-02-27 BR BR112019016490A patent/BR112019016490A2/pt unknown
- 2018-02-27 US US15/906,773 patent/US10556950B2/en active Active
- 2018-02-27 CN CN201880008302.XA patent/CN110382528A/zh active Pending
- 2018-02-27 MX MX2019009945A patent/MX2019009945A/es unknown
- 2018-02-27 PE PE2024001024A patent/PE20241514A1/es unknown
- 2018-02-27 WO PCT/IB2018/000249 patent/WO2018154390A1/fr not_active Ceased
- 2018-02-27 EA EA201991726A patent/EA201991726A1/ru unknown
- 2018-02-27 SG SG10201913419TA patent/SG10201913419TA/en unknown
- 2018-02-27 EP EP18718907.1A patent/EP3585810B1/fr active Active
- 2018-02-27 JP JP2019545918A patent/JP7165996B2/ja active Active
- 2018-02-27 KR KR1020197024146A patent/KR102701634B1/ko active Active
- 2018-02-27 AR ARP180100454A patent/AR110875A1/es unknown
- 2018-02-27 IL IL267945A patent/IL267945B2/en unknown
- 2018-02-27 CR CR20190363A patent/CR20190363A/es unknown
- 2018-02-27 MA MA047608A patent/MA47608A/fr unknown
- 2018-02-27 MY MYPI2019004787A patent/MY193821A/en unknown
- 2018-02-27 CN CN202010117151.0A patent/CN111320695B/zh active Active
- 2018-02-27 GE GEAP202215170A patent/GEAP202215170A/en unknown
- 2018-02-27 CA CA3052538A patent/CA3052538A1/fr active Pending
- 2018-02-27 GE GEAP201815170A patent/GEP20227392B/en unknown
- 2018-02-27 AU AU2018224390A patent/AU2018224390C1/en active Active
2019
- 2019-08-09 NI NI201900086A patent/NI201900086A/es unknown
- 2019-08-13 CL CL2019002296A patent/CL2019002296A1/es unknown
- 2019-08-13 CO CONC2019/0008786A patent/CO2019008786A2/es unknown
- 2019-08-15 DO DO2019000215A patent/DOP2019000215A/es unknown
- 2019-08-20 MX MX2023013246A patent/MX2023013246A/es unknown
- 2019-08-20 PH PH12019501929A patent/PH12019501929A1/en unknown
- 2019-08-22 AR ARP190102386A patent/AR117952A2/es unknown
2020
- 2020-01-17 US US16/746,725 patent/US10894829B2/en active Active
- 2020-12-15 US US17/122,325 patent/US11739143B2/en active Active
2021
- 2021-09-13 CL CL2021002389A patent/CL2021002389A1/es unknown
2022
- 2022-10-18 JP JP2022166859A patent/JP2023002670A/ja active Pending
2024
- 2024-02-02 CL CL2024000339A patent/CL2024000339A1/es unknown
- 2024-08-28 JP JP2024146101A patent/JP2024170459A/ja active Pending

Also Published As

Publication number	Publication date
US11739143B2 (en)	2023-08-29
NI201900086A (es)	2019-10-08
IL267945B2 (en)	2025-10-01
CN111320695B (zh)	2021-09-03
AU2018224390C1 (en)	2025-04-17
CA3052538A1 (fr)	2018-08-30
GEP20227392B (en)	2022-06-27
JP2023002670A (ja)	2023-01-10
JP2018139530A (ja)	2018-09-13
BR112019016490A2 (pt)	2020-04-07
AR110875A1 (es)	2019-05-08
AU2018224390B2 (en)	2024-10-31
US20200223916A1 (en)	2020-07-16
PE20241514A1 (es)	2024-07-19
KR102701634B1 (ko)	2024-08-30
TW202506718A (zh)	2025-02-16
SG11201907548PA (en)	2019-09-27
MX2023013246A (es)	2023-11-21
MX2019009945A (es)	2019-11-05
GEAP202215170A (en)	2022-02-10
TW201843179A (zh)	2018-12-16
TWI848904B (zh)	2024-07-21
JP2020508666A (ja)	2020-03-26
CL2024000339A1 (es)	2024-08-16
CR20190363A (es)	2019-11-05
MY193821A (en)	2022-10-27
US20210380677A1 (en)	2021-12-09
CL2019002296A1 (es)	2019-11-29
EA201991726A1 (ru)	2020-01-30
JP2024170459A (ja)	2024-12-10
EP3585810B1 (fr)	2025-11-26
JOP20180014A1 (ar)	2019-01-30
US10894829B2 (en)	2021-01-19
JP7165996B2 (ja)	2022-11-07
CO2019008786A2 (es)	2019-08-20
AU2018224390A1 (en)	2019-07-11
WO2018154392A1 (fr)	2018-08-30
PE20191614A1 (es)	2019-11-05
CN110382528A (zh)	2019-10-25
CN111320695A (zh)	2020-06-23
CL2021002389A1 (es)	2022-04-22
DOP2019000215A (es)	2019-09-30
EP3585810A1 (fr)	2020-01-01
IL267945B1 (en)	2025-06-01
US10556950B2 (en)	2020-02-11
IL267945A (en)	2019-09-26
SG10201913419TA (en)	2020-03-30
PH12019501929A1 (en)	2020-06-29
AR117952A2 (es)	2021-09-08
US20180346564A1 (en)	2018-12-06
WO2018154390A1 (fr)	2018-08-30
KR20190122674A (ko)	2019-10-30

Publication	Publication Date	Title
MA47608A (fr)	2020-01-01	Anticorps humanisé pour le traitement ou la prévention de troubles cognitifs, son procédé de production et agent pour le traitement ou la prévention de troubles cognitifs l'utilisant
FR24C1017I2 (fr)	2024-10-25	Utilisations d'antagonistes d'il-13 pour le traitement de la dermatite atopique
MA50786A (fr)	2022-04-27	Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
MA49279A (fr)	2020-02-05	Compositions d'anticorps optimisées pour le traitement de troubles oculaires
EP3484577A4 (fr)	2020-03-25	Procédés et systèmes de traitement de troubles pelviens et d'affections douloureuses
EP3615521A4 (fr)	2021-02-17	Procédés d'amélioration de la mémoire et de la cognition, et de traitement des troubles de la mémoire et des troubles cognitifs
EP3600281A4 (fr)	2020-03-18	Traitement d'association pour le traitement ou la prévention de tumeurs
EP3542804A4 (fr)	2020-05-27	Composition pharmaceutique pour prévenir ou traiter un cancer cérébral comprenant un polymorphe cristallin d'hexoxyde de tétraarsenic, et son procédé de préparation
EP3604513A4 (fr)	2021-01-06	Composition pour la production de tagatose et procédé de production de tagatose l'utilisant
MA50803A (fr)	2020-09-30	Polynucléotides codant pour l'ornithine transcarbamylase pour le traitement de troubles du cycle de l'urée
EP3400061A4 (fr)	2019-11-20	Système de photothérapie pour le traitement d'affections nasales
EP3429605A4 (fr)	2019-09-18	Agent thérapeutique pour le traitement de maladies, notamment les maladies touchant le système nerveux central
EP3819284A4 (fr)	2022-04-20	Catalyseur pour la préparation de 1,2-pentanediol et procédé de préparation de 1,2-pentanediol l'utilisant
EP3704108A4 (fr)	2021-08-25	Composés et compositions pour le traitement de troubles hématologiques
EP3778619A4 (fr)	2021-06-30	Segment pour la synthèse d'oligonucléotides, procédé de production correspondant et procédé de synthèse d'oligonucléotides l'utilisant
EP3421506A4 (fr)	2019-05-29	Catalyseur supporté de type métallocène et procédé de production de polypropylène l'utilisant
EP3630102A4 (fr)	2021-04-14	Formulations pour le traitement d'un trouble de stress post-traumatique
EP3606520A4 (fr)	2021-01-06	Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement des troubles coronaires
EP3496715A4 (fr)	2020-01-22	Composés utiles pour modifier les taux d'acides biliaires pour le traitement du diabète et de maladies cardiométaboliques.
EP3728567A4 (fr)	2021-09-22	Procédés pour le développement de produits pharmaceutiques pour le traitement d'affections neurodégénératives
EP3529234A4 (fr)	2020-03-11	Composés, procédé d'obtention des composés, composition pharmaceutique, utilisation des composés et procédé de traitement de troubles psychiatriques et/ou de troubles du sommeil
EP3858483A4 (fr)	2022-01-19	Catalyseur pour ammoxydation de propylène, son procédé de préparation et procédé d'ammoxydation de propylène l'utilisant
EP3573616C0 (fr)	2025-12-10	Nouvel inhibiteur du protéasome spiro et cyclique bis-benzylidine pour le traitement du cancer, du diabète et de troubles neurologiques
EP3730144A4 (fr)	2021-09-01	Agent pour le traitement d'une maladie du système nerveux
EP3398614A4 (fr)	2019-12-25	Agent pour la prévention et/ou le traitement de la maladie d'alzheimer